Page 86 - PRESENTATION

Conclusion

• Significant progress in this disease

• Maintenance Avelumab is the new standard of care in patients

with SD, PR, CR on front line chemotherapy

• Front line combinations not superior (Chemo+Pembro,

Chemo+Atezo, Durva+Tremi) to chemotherapy

• 2 -line immune checkpoint inhibitors only effective in a minority
nd

• Enfortumab Vedotin moving into third line

• How best to sequence all these new treatments?